Scott Alan Peslak, MD, PhD

he/him/his
Hematology
Accepting new patients
Sees patients age 18 and up
Penn Blood Disorders Center
Headshot of Scott Alan Peslak, MD, PhD
Penn Medicine Provider

About me

  • Gene Therapy Lead, Comprehensive Sickle Cell Program and Comprehensive Adult Thalassemia Program
  • Assistant Professor of Medicine (Hematology-Oncology)
  • Assistant Professor of Pediatrics

I am a physician-scientist at the University of Pennsylvania and I care for patients in the Penn Medicine Comprehensive Sickle Cell Disease Program and Comprehensive Adult Thalassemia Program. In addition to my clinical focus on red cell disorders, I also run a laboratory studying novel regulators of fetal hemoglobin and new genetic and pharmacologic therapies for the treatment of sickle cell disease.

My education and training

  • Medical School: University of Rochester School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Peslak is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Cheng A.N., Peslak S.A., Sheth S., Sayani F., Lal A. High morbidity in adults with non-transfusion-dependent thalassemia referred to U.S. specialty centers , American Society of Hematology Annual Meeting, Orlando, FL: 2025


Castracani C.C., Bright M., Patel J., Peslak S.A., Cheng A., Breda L., Rivella S., Kwiatkowski J. Real-world comparative effects of curative and disease-modifying therapies on ineffective erythropoiesis in beta-thalassemia , American Society of Hematology Annual Meeting, Orlando, FL: 2025


Cheng A.N., Gimotty P., Margolis D., Peslak S.A., Al-Samkari H, Roe A.H., Kwiatkowski J.L. Development of a Prediction Model for Maternal Pregnancy Complications in Sickle Cell Disease , American Society of Hematology Annual Meeting, Orlando, FL: 2025


Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. Real-world safety profile of twice-daily deferiprone for iron overload in patients with thalassemia syndromes , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025


Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. Real-world safety profile of twice-daily deferiprone for iron overload in patients with sickle cell disease , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025


Cheng A.N, Peslak S.A., Sheth S., Sayani S., Lal A. High Morbidity in Adults with Non-Transfusion-Dependent Thalassemia Referred to U.S. Specialty Centers , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025


Al Ta’ani, O.; Mayrer, B.M.; Luche, N.M.; Siddique, S.M., Peslak, S.A.; Anderson, T.S.; Vajravelu, R.K. Impact of Diagnostic Serum Ferritin Thresholds on Prevalence of Iron Deficiency Anemia: A Cross-Sectional Analysis of U.S. Adults , JAMA Internal Medicine, Online Ahead of Print: 2025,e252311


Cheng A.N., Cohen J., Lundberg R.K., Sayani F.A., Chong E.A., Peslak S.A. Progressive Anaemia and Splenomegaly in an Adult with HbE/Beta Thalassaemia , 1st TIF Pan American Conference on Thalassaemia and Other Haemoglobin Disorders, Washington, DC.: 2025


Huang, P., Peslak, S.A., Shehu, V., Keller, C.A., Giardine, B., Shi, J., Hardison, R.C., Blobel, G.A., Khandros, E. Let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching , Blood, 143(19): 2024,1980-1991


Peslak S.A., Abbas T., Khandros E., Traxler E.A., Abdulmalik O., Giardine B.M., Keller C.A., Hardison R.C., Shi J., Blobel G.A. Protein Phosphatase 6 Complex: Novel Regulator of Fetal Hemoglobin and Potential Therapeutic Target in Sickle Cell Disease. , American Society of Hematology Annual Meeting, San Diego, CA: 2023


View all publications